Skip to main content

31/01/2014 | 07:30 CET | Group Announcements

Sonova proposes Stacy Enxing Seng for election to the Board of Directors

Staefa (Switzerland), 31 January 2014 – Sonova Holding AG, the world’s leading provider of hearing solutions, announces today that its Board of Directors nominates Stacy Enxing Seng as a new board member for election at the next Annual General Meeting in June 2014. Ms. Enxing Seng is currently serving as President of Covidien’s global  Vascular Therapies business.

"We are very pleased to propose Ms. Enxing Seng as a new member to the Board of Directors.  Drawing on her impressive track record in growing startups and leading multinational companies, she will be a very important addition to the current Board of Directors. Ms. Enxing Seng's extensive experience in the medtech industry and her commitment to innovation will bring most valuable perspectives to Sonova," says Robert Spoerry, Chairman of the Board of Directors of Sonova Holding AG.


Ms. Enxing Seng (born in 1964, US citizen) is currently responsible for managing a global organization of approximately 4,000 employees with $1.6 billion in revenue. She joined Covidien in July 2010 through the ev3 acquisition where she was a founding member and executive officer responsible for leading ev3's peripheral vascular division from inception to a $350 million business. Ms. Enxing Seng has held various positions of increasing responsibility in the healthcare and medtech industry. She received a Master of Business Administration from Harvard University and has a Bachelor of Arts in Public Policy from Michigan State University.


"I am delighted to join the Board of Directors of Sonova," said Ms. Enxing Seng. "I have always been passionate about the healthcare and medtech industry, making a difference in the lives of others. I am excited to become part of a growing company which is offering highly innovative products, allowing people with hearing loss to live better lives."


– End –